Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

From advances in targeted therapies to the integration of AI and steps towards precision medicine, 2024 brought many exciting developments in the field. With 2025 now unfolding, many of these are likely to continue gaining momentum and potentially redefine patient care. In this latest edition of touchREVIEWS in RMD, we’re excited to present a collection […]

Alopecia Areata

An Introduction to Alopecia Areata

Mark CompleteCompleted
BookmarkBookmarked

As touchIMMUNOLOGY approaches 20 years of providing education for busy immunologists, we are looking to the future—and it certainly looks bright!

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

Mark CompleteCompleted
BookmarkBookmarked

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Recent advancements made in understanding the pathology of inflammatory skin conditions have enabled JAK inhibitors, initially developed for haematology over 20 years ago, to be investigated for dermatological use. In this episode, Dr William (Bill) Damsky discusses JAK inhibitors’ journey from proof-of-concept to treating a wide range of skin conditions, their future impact on rare diseases and the debate around safety.

35 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchIN CONVERSATION
Dr Maryanne M Senna, Dr Anna Waśkiel-Burnat

Watch two expert dermatologists discuss AA, focusing on issues related to disease severity, pathophysiology and treatment with JAK inhibitors.

Coverage from: EADV

It was an absolute pleasure to be able to speak with Dr Brett King (Yale School of Medicine, New Haven, CT, USA) about the recent efficacy and safety results presented around the JAK inhibitors, baricitinib and ritlecitinib, in the treatment of alopecia areata.  His presentations entitled 'Efficacy and Safety of Ritlecitinib (PF-06651600) in Patients with Alopecia Areata and ≥50% Scalp Hair Loss: Results from the International ALLEGRO Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Study' and 'Efficacy and safety of baricitinib in adults with alopecia areata: Phase 3 results from two randomized controlled trials (BRAVE-AA1 and BRAVE-AA2)' were given at the EADV 30th Congress, 29 Sep - 2 Oct. Questions Could you tell us a little about the ALLEGRO and BRAVE clinical trials, their design and patient populations? (0:14) What were the efficacy and safety findings from these studies and how do they compare? (1:47) With two JAK inhibitors appearing promising in this indication, what are their relative strengths and limitations? (3:47) Disclosures: Dr. Brett King has served on advisory boards and/or is a consultant and/or is a clinical trial investigator for Abbvie, Aclaris Therapeutics Inc, AltruBio Inc, Almirall, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol-Myers Squibb, Concert Pharmaceuticals Inc, Dermavant Sciences Inc, Eli Lilly and Company, Incyte Corp, LEO Pharma, Otsuka/Visterra Inc, Pfizer Inc, Regeneron, Sanofi Genzyme, TWi Biotechnology Inc, and Viela Bio. He is on speaker bureaus for Pfizer Inc, Regeneron and Sanofi Genzyme Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival. Filmed in coverage of the EADV’s 30th Congress, 29 Sep – 2 Oct 2021. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

touchIMMUNOLOGY caught up with William (Bill) Damsky (Yale School of Medicine, New Haven, CT, USA) to discuss hot topics and current educational needs in the treatment of alopecia areata. Disclosures: William Damsky is a consultant for Eli Lilly, Pfizer, and ...

touchIMMUNOLOGY caught up with William (Bill) Damsky (Yale School of Medicine, New Haven, CT, USA) to discuss the results from the BRAVE AA1 study (NCT03570749) investigating the use of baricitinib in the treatment of alopecia areata. Questions What is the ...

Alopecia areata (AA) is a common dermatological disorder characterized by hair loss of the scalp and/or body, which is often resistant to treatment. It has a substantial impact on body image and self-esteem, resulting in greatly reduced quality of ...

Load More...
Close Popup